https://rijournals.com/scientific-and-experimental-sciences/

RESEARCH INVENTION JOURNAL OF SCIENTIFIC AND EXPERIMENTAL SCIENCES 5(1):57-61, 2025

©RIJSES Publications

ONLINE ISSN: 1115-618X

PRINT ISSN: 1597-2917

https://doi.org/10.59298/RIJSES/2025/515761

Automation in Drug Manufacturing: Ensuring Quality and Safety

Kungu Erisa

Faculty of Pharmacy Kampala International University Uganda

Email: erisa.kungu@studwc.kiu.ac.ug

ABSTRACT

The pharmaceutical industry is increasingly adopting automation to enhance the quality, safety, and efficiency of drug manufacturing. Automation addresses challenges such as human error, variability in production, and regulatory compliance while improving drug availability and cost-effectiveness. This paper examines the role of automation in drug manufacturing, the regulatory frameworks governing automated processes, key technological advancements, benefits, and challenges. It also presents case studies of successful implementation, demonstrating automation's potential in improving drug production. Despite challenges such as high initial costs and integration complexities, automation remains a crucial advancement in ensuring consistent, high-quality pharmaceutical products.

Keywords: Automation, drug manufacturing, pharmaceutical industry, quality control, regulatory compliance, robotics, artificial intelligence.

INTRODUCTION

Drug manufacturing has grown from small-scale production to large, highly automated facilities that manufacture large batches of a single, complex medication. Over time, products have evolved from basic chemical compounds to complex biologic molecules. Automation has been incorporated into facilities in large part to ensure the quantity that is being demanded by these newer and different products can be created. However, making a change from manual manufacturing to a highly automated facility doesn't come without its challenges, and the move to automation is slow in the pharmaceutical industry. Producing a drug product is a lengthy process. It can take years for an idea to evolve into a drug product that has been thoroughly studied and validated, and products must be tested to ensure both quality and purity. This means that one change in production can delay the approval and availability of a drug for years and drive costs sky-high. Given the time and costs involved, facilities need to be designed in a way that can both increase drug product yield and quality while also being cost-effective. Many companies have turned to different technologies to automate the production process and adhere to strict regulatory standards—from production to packaging technologies, and monitoring and control systems. Drivers for the increased level of automation include the ability to control quality with less human variability and in less time; help make processes greener and therefore more cost-effective; and increase drug availability, reducing exorbitant drug costs. Automating the manufacturing and distribution processes increases the demand for more standardized equipment, such as packaging and assembly equipment. The technology has been qualified and certified, speeding time to market [1, 2, 3].

Regulatory Frameworks and Guidelines for Automated Drug Manufacturing

Regulatory authorities and international organizations define the general framework for the production of pharmaceuticals, including biotech products. The most important regulatory authorities are the Food and Drug Administration and the European Medicines Agency. They are responsible for ensuring the safety, efficacy, and quality of therapeutic agents and are addressing the concerns of consumers and professional healthcare societies regarding the variety of biological and biopharmaceutical products. Regulations, recommendations, and guidelines have been established concerning the efficacy and/or safety of biological and biotechnological healing products and focus on the requirements and conditions applied for design,

development, manufacturing procedures, and quality management to ensure both product safety and efficacy. The Good Manufacturing Practice implies that pharmaceutical manufacturers must ensure their products are consistently produced to the established quality attributes according to predefined requirements [4, 5, 6]. The main reason for all these demanding requirements is, of course, the assurance of quality for the patient using different drugs, particularly if they are biological and/or therapeutically active. The GMP concept is flexible enough to support manufacturing with respect to innovation, automation, new technologies, and the application of process analytical technologies. This wide acceptance is, in turn, necessary, especially for the nascent field of ATMPs, as this will ensure the great variety in development and manufacturing procedures, systems, and machines. The most important part of this GMP requirement is that all qualitatively relevant steps, actions, tools, and devices concerning manufacturing, testing, and, consequently, release of the products may be supervised and are also documented. The rapidity and varying nature of new technologies might be surprisingly challenging in quality control and regulation, which is mandated by official regulatory organizations. Experts must raise awareness and initiate consultation with regulatory authorities to establish 'quality' by design-added and automated manufacturing processes [7, 8, 9].

Key Technologies and Systems in Automated Drug Manufacturing

A variety of technologies and tools are available for the pharmaceutical and biopharmaceutical manufacturing industries to be used in production automation. These include, but are not restricted to, robotics, different types of process control systems, monitoring systems, and analytics in the IT environment or embedded within instruments. These technologies enable seamless and autonomous manufacturing by automating distinct segments of the production process [10, 11, 1]. Another represented technology in drug manufacturing is robotics. It can be used to perform many different production steps such as transportation, liquid handling, weighing, dispensing, and inspection of components and/or finished drug products. These systems are mainly used in the formulation and filling environment, generally for the automation of visual inspection, aseptic manipulations, or filling procedures. High throughput in filling applications is another use case of automation through robotics. Over the course of the last number of years, novel robotics systems have entered the manufacturing environment, striving to improve manufacturing by achieving flexibility, smaller footprint, and mobility of the robotic arms. Broadly speaking, the implementation of automation into drug manufacturing systems is desirable, as it removes the human element from production processes, reducing the risk of human error and providing an opportunity to speed up production times. Although these systems offer an extent of automation, a master controller's input is fundamental. This is tied to assuring good integration of separation of functions among the different systems to make sure the new systems can be smoothly connected with existing systems [12, 13, 14]. In order to build a vision of the digital and automated future of pharmaceutical production, it is important to recognize that artificial intelligence will have a strong influence in the field of drug product manufacturing. Artificial intelligence introduces new methodologies for decision support, automation, and self-learning systems. These last two aims can be generally traced back to machine learning, an AI branch. The capabilities of decision support and process automation are already part of some large-scale pharmaceutical digitalization activities, like most of the recently released commercial equipment for process analytical technology, machine analytics, and monitoring for continuous manufacturing of drug products at small to middle scales. On a more specific level, neural network technologies are approaching maturity for the sorts of multivariate data analyses and predictions for which software is historically used. A contemporary phenomenon, which is likely to become a prominent presence in industrial applications, is the expansion of AI into robotization architectures. This is already going on in the automotive business, and the pharmaceutical industry is also very active in promoting an adoption culture. Process analytical technology is evolving towards machine learning technologies, too. The manufacturing strategy in today's world is, to a limited degree, based on the combined advantages of emerging bio-based technologies. If current development tendencies extend themselves, the pharmaceutical industry faces the literal prospect of being run on a digital production manufacturing system. It must therefore continuously assess these technologies and offer an incentive to invest in them to stay competitive [15, 16, 17].

Benefits and Challenges of Automation in Drug Manufacturing

Many stakeholders agree that implementing some level of automation in drug manufacturing makes sense from the standpoint of quality, scale, flexibility, and timeliness. Technological advances could support operational efficiency, ensure data transparency, and promote a 'quality-by-design' approach. The available robotics technologies empower industries to address these issues effectively. Robotics is not only augmenting the available manufacturing capabilities but is also extensively used to address regulatory

compliance. Automation is expected to provide greater profitability, improved product quality, regulatory compliance, better site and workforce management, and environmental preservation. Implementing automation technologies, such as robotics and other digital tools, to perform routine tasks repeatedly helps to advance productivity and maintain workforce health and safety. Automated lines are capable of performing real-time product quality control to ensure that the end product is of high quality and meets market requirements. A related benefit is the systems' ability to provide rapid feedback directing adjustments to meet stringent product specifications, optimizing efficiency and throughput capabilities in facilities. However, automation does present challenges. The upfront investment costs are high, as are the complexity components and systems integration challenges when working with established legacy systems already in place. The solution requires a combination of technological and organizational changes, and the challenge must be addressed systematically to realize successful adoption. New skills, retraining, and talent management are also required when incorporating robotics and digital tools in a facility. The human-robot interface must also be carefully integrated. [18, 19, 20].

Case Studies: Successful Implementation of Automated Systems in Drug Manufacturing

Case Study A: Antares Pharma

Pharmaceutical company Antares Pharma has implemented several automation systems in many of its drug manufacturing plants. Antares utilized technology to create a fluid-filling automation system for a cartridge that has been repurposed to contain ready-to-use finished drugs with new drug ingredients and formulations in a robotic system at its automated facility in Wilmington. The system has improved the yield of finished drugs substantially and cut production costs by up to 60%. The added safety benefit is that employees do not have to handle the drug or the equipment it is being manufactured on. Factors that helped the company achieve success with manufacturers of aseptically filled drugs being filled in syringes and cartridges include focusing on one clinical pipeline product from the beginning, strategic planning, and involving the entire plant personnel. Early quality-by-design discussions with stakeholders were the keys to gain fast approval and to validate the process and the machines, minimizing any potential downtime. Maintenance is performed as needed under continuous improvement projects for the automated machines and lines [21, 22, 23].

Case Study B: Dyport Laboratories

Dyport, a joint venture of Dart Neuroscience and Teva Pharmaceuticals, began construction of a 100,000-square-foot, fully automated drug manufacturing plant in early 2015. A construction company will install all the integrated machinery and systems for the new plant. Strategies that Dyport will use to make the all-robot startups successful include flexible, modular equipment, and automated technologies, such as an aseptic small-scale filler with a glove box isolator, a video management system to monitor operations, and a high-speed automated inspection system [24, 25, 26].

CONCLUSION

Automation in drug manufacturing is revolutionizing the pharmaceutical industry by improving efficiency, ensuring quality, and enhancing safety. Through robotics, AI, and advanced process control systems, companies can meet stringent regulatory requirements while optimizing production. Although the transition to automation presents challenges, such as high costs and the need for skilled personnel, the long-term benefits outweigh the initial investments. Successful implementations in companies like Antares Pharma and Dyport Laboratories highlight automation's potential in reducing costs, minimizing human error, and accelerating drug availability. As technology advances, automation will play a pivotal role in shaping the future of pharmaceutical manufacturing, ensuring that high-quality medications reach patients faster and more reliably.

REFERENCES

1. Haleem A, Javaid M, Singh RP, Rab S, Suman R. Hyperautomation for the enhancement of automation in industries. Sensors International. 2021 Jan 1;2:100124.
2. Ajiga D, Okeleke PA, Folorunsho SO, Ezeigweneme C. The role of software automation in improving industrial operations and efficiency. International Journal of Engineering Research Updates. 2024;7(1):22-35. researchgate.net
3. Javaid M, Haleem A, Singh RP, Suman R. Enabling flexible manufacturing system (FMS) through the applications of industry 4.0 technologies. Internet of Things and Cyber-Physical Systems. 2022 Jan 1;2:49-62. sciencedirect.com
4. Elsallab M, Maus MV. Expanding access to CAR T cell therapies through local manufacturing. Nature biotechnology. 2023 Dec;41(12):1698-708.
5. Alliance for Regenerative Medicine (ARM), European Federation of Pharmaceutical Industries and Associations (EFPIA), European Association for Bioindustries (EuropaBio), Beattie S. Call

for more effective regulation of clinical trials with advanced therapy medicinal products consisting of or containing genetically modified organisms in the European Union. Human Gene Therapy. 2021 Oct 1;32(19-20):997-1003. [HTML]

6. Wang CK, Tsai TH, Lee CH. Regulation of exosomes as biologic medicines: Regulatory challenges faced in exosome development and manufacturing processes. Clinical and Translational Science. 2024 Aug;17(8):e13904. wiley.com
7. Hole G, Hole AS, McFalone-Shaw I. Digitalization in pharmaceutical industry: What to focus on under the digital implementation process?. International Journal of Pharmaceutics: X. 2021 Dec 1;3:100095.
8. Johanna I, Daudeij A, Devina F, Nijenhuis C, Nuijen B, Romberg B, de Haar C, Haanen J, Dolstra H, Bremer E, Sebestyen Z. Basics of advanced therapy medicinal product development in academic pharma and the role of a GMP simulation unit. Immuno-Oncology and Technology. 2023 Dec 1;20:100411. sciencedirect.com
9. Lugovoi I, Andritsos DA, Senot C. Manufacturing process innovation in the pharmaceutical industry. Manufacturing & Service Operations Management. 2022 May;24(3):1760-78. [HTML]
10. Nee AY. Handbook of manufacturing engineering and technology. Springer Publishing Company, Incorporated; 2014 Oct 15.
11. Sahoo S, Lo CY. Smart manufacturing powered by recent technological advancements: A review. Journal of Manufacturing Systems. 2022 Jul 1;64:236-50.
12. Leal F, Chis AE, Caton S, González–Vélez H, García–Gómez JM, Durá M, Sánchez–García A, Sáez C, Karageorgos A, Gerogiannis VC, Xenakis A. Smart pharmaceutical manufacturing: ensuring end-to-end traceability and data integrity in medicine production. Big Data Research. 2021 May 15;24:100172. sciencedirect.com
13. Ashima R, Haleem A, Bahl S, Javaid M, Mahla SK, Singh S. Automation and manufacturing of smart materials in Additive Manufacturing technologies using Internet of Things towards the adoption of Industry 4.0. Materials Today: Proceedings. 2021 Jan 1;45:5081-8. [HTML]
14. Sharma M, Sehrawat R, Luthra S, Daim T, Bakry D. Moving towards industry 5.0 in the pharmaceutical manufacturing sector: Challenges and solutions for Germany. IEEE Transactions on Engineering Management. 2022 Feb 11. [HTML]
15. Bender A, Cortés-Ciriano I. Artificial intelligence in drug discovery: what is realistic, what are illusions? Part 1: Ways to make an impact, and why we are not there yet. Drug discovery today. 2021 Feb 1;26(2):511-24.
16. Arden NS, Fisher AC, Tyner K, Lawrence XY, Lee SL, Kopcha M. Industry 4.0 for pharmaceutical manufacturing: Preparing for the smart factories of the future. International Journal of Pharmaceutics. 2021 Jun 1;602:120554. sciencedirect.com
17. Elbadawi M, McCoubrey LE, Gavins FK, Ong JJ, Goyanes A, Gaisford S, Basit AW. Harnessing artificial intelligence for the next generation of 3D printed medicines. Advanced Drug Delivery Reviews. 2021 Aug 1;175:113805. ucl.ac.uk
18. Sardella M, Belcher G, Lungu C, Ignoni T, Camisa M, Stenver DI, Porcelli P, D'Antuono M, Castiglione NG, Adams A, Furlan G. Monitoring the manufacturing and quality of medicines: a fundamental task of pharmacovigilance. Therapeutic Advances in Drug Safety. 2021 Aug;12:20420986211038436. sagepub.com
19. Javaid M, Haleem A, Singh RP, Suman R. Significance of Quality 4.0 towards comprehensive enhancement in manufacturing sector. Sensors International. 2021 Jan 1;2:100109.
20. McDermott O, Antony J, Sony M, Daly S. Barriers and enablers for continuous improvement methodologies within the Irish pharmaceutical industry. Processes. 2021 Dec 30;10(1):73.
21. Pérez Santín E, Rodríguez Solana R, González García M, García Suárez MD, Blanco Díaz GD, Cima Cabal MD, Moreno Rojas JM, López Sánchez JI. Toxicity prediction based on artificial intelligence: A multidisciplinary overview. Wiley Interdisciplinary Reviews: Computational Molecular Science. 2021 Sep;11(5):e1516. [HTML]
22. Amselem S, Kogan D, Loboda O, Levy A, Feuchtwanger Y, Bavli D. Monoclonal Antibodies from Space: Improved Crystallization Under Microgravity During Manufacturing in Orbit. Journal of Exploratory Research in Pharmacology. 2024 Jun 25;9(2):96-105. xiahepublishing.com
23. Mathew R, McGee R, Roche K, Warreth S, Papakostas N. Introducing Mobile Collaborative Robots into Bioprocessing Environments: Personalised Drug Manufacturing and Environmental Monitoring. Applied Sciences. 2022 Oct 27;12(21):10895.

24. Delle Chiaie T. Diplopia Secondary to Neurotoxin Injections: Prevention, Diagnosis, and Management. The Journal of Clinical and Aesthetic Dermatology. 2024 Mar;17(3-4 Suppl 1):S30.
25. de Lamotte JD, Perrier A, Martinat C, Nicoleau C. Emerging Opportunities in Human Pluripotent Stem-Cells Based Assays to Explore the Diversity of Botulinum Neurotoxins as Future Therapeutics. International Journal of Molecular Sciences. 2021 Jul;22(14). nih.gov
26. Willis A. Research provides new insight into the medical aesthetics sector. Journal of Aesthetic Nursing. 2017 Sep 2;6(7):374-5.

CITE AS: Kungu Erisa (2025). Automation in Drug Manufacturing: Ensuring Quality and Safety. RESEARCH INVENTION JOURNAL OF SCIENTIFIC AND EXPERIMENTAL SCIENCES 5(1):57-61. https://doi.org/10.59298/RIJSES/2025/515761